PML stands for progressive multifocal leukoencephalopathy, a rare and serious brain infection. It’s caused by a common virus called the JC virus, which roughly 61% of the general population carries without ever knowing it. In most people, the virus stays dormant and harmless. PML happens when a severely weakened immune system allows the virus to reactivate and attack the brain’s white matter.
How the JC Virus Causes Brain Damage
The JC virus is widespread and typically picked up during childhood or adolescence. A healthy immune system keeps it in check indefinitely, usually in the kidneys and bone marrow. The virus only becomes dangerous when the immune system is deeply compromised and can no longer suppress it.
Once reactivated, the JC virus targets the cells responsible for producing myelin, the protective coating around nerve fibers in the brain. As these cells are destroyed, patches of white matter lose their insulation. Nerve signals slow down or stop entirely, and the damage spreads across multiple areas of the brain. The name itself describes this process: “progressive” (worsening over time), “multifocal” (affecting multiple brain regions), and “leukoencephalopathy” (disease of the white matter).
Who Is at Risk
PML almost exclusively affects people with severely weakened immune systems. The most common underlying conditions include:
- HIV/AIDS, particularly when the infection is untreated or advanced
- Blood and bone marrow cancers like leukemia
- Lymphatic system cancers like lymphoma or Hodgkin disease
- Autoimmune diseases such as multiple sclerosis, lupus, or rheumatoid arthritis
- Organ transplant recipients taking drugs to prevent rejection
Certain medications also raise the risk. Natalizumab, a drug commonly prescribed for multiple sclerosis and Crohn’s disease, is one of the most well-known triggers. Other drugs linked to PML include rituximab (used for lymphoma and autoimmune conditions), corticosteroids like prednisone, fumarate (another MS treatment), and several chemotherapy agents. Combination regimens involving four or more immune-suppressing drugs carry elevated risk as well.
Symptoms to Recognize
PML symptoms develop over days to weeks and worsen steadily. Because the virus can strike different parts of the brain, symptoms vary from person to person depending on which areas are damaged. The most common signs include cognitive problems like confusion, memory loss, and difficulty concentrating. Many people develop weakness on one side of the body, trouble walking or coordinating movements, and changes in vision such as blind spots or loss of peripheral vision. Speech and language difficulties can also appear.
What makes PML particularly concerning is its pace. Unlike conditions that plateau, PML symptoms tend to compound. New deficits emerge as additional brain regions are affected, and existing ones get worse. In someone with a known immunosuppressive condition or medication history, these neurological changes should raise immediate concern.
How PML Is Diagnosed
Brain MRI is the primary tool for identifying PML. On imaging, PML lesions appear as bright areas on certain scan types, located in the white matter just beneath the brain’s surface. These lesions can be in a single spot or scattered across multiple regions. One distinguishing feature is that PML lesions typically don’t cause significant swelling or compress surrounding brain tissue, unlike tumors or abscesses.
Doctors also look at whether lesions change over time. If suspicious areas on an MRI remain stable over several weeks to a few months on repeat scans, PML becomes less likely. A spinal tap to test for JC virus DNA in the cerebrospinal fluid helps confirm the diagnosis. Combined with the patient’s immune status and clinical symptoms, these findings together establish whether PML is present.
Treatment and Immune Recovery
There is no antiviral drug that directly kills the JC virus. The primary strategy is restoring the immune system so the body can fight the infection on its own. For people with HIV, this means starting or optimizing antiretroviral therapy immediately. For patients on immune-suppressing medications, the offending drug is typically stopped or reduced.
This approach creates a difficult tradeoff. As the immune system recovers, it can mount an aggressive inflammatory response against the infected brain tissue, a complication called immune reconstitution inflammatory syndrome (IRIS). IRIS can cause swelling and pressure in the brain, sometimes making neurological symptoms temporarily worse before they improve. It’s more common in people with very low immune function at the time treatment begins. In severe cases where brain swelling threatens serious harm, corticosteroids may be used short-term to control the inflammation, though antiretroviral therapy is continued throughout.
Survival and Outlook
PML remains a serious diagnosis with high mortality. The overall one-year mortality rate is approximately 38%, but outcomes vary dramatically depending on the underlying cause. People with HIV-related PML who receive effective antiretroviral therapy have significantly better prospects: one study found a median survival of about 4.3 years and a one-year mortality rate of roughly 26%. The introduction of modern HIV treatment raised median survival from under 5 months to about 1.8 years, and outcomes continue to improve with earlier detection.
For people who develop PML from other causes, such as cancer treatments, organ transplant drugs, or autoimmune disease therapies, the prognosis is considerably worse. The median survival in non-HIV patients was just 184 days (about 6 months) in one study, with a one-year mortality rate of 60% and overall mortality reaching 80%. The difference largely comes down to reversibility: HIV-related immune suppression can be directly treated with antiretrovirals, while restoring immune function in other contexts is often slower or less complete.
Among survivors, the degree of disability at diagnosis is one of the strongest predictors of long-term outcome. People diagnosed earlier, before extensive brain damage has occurred, tend to fare better regardless of the underlying condition.
Monitoring for People on High-Risk Medications
If you take natalizumab or another medication known to increase PML risk, your doctor will likely test your blood for JC virus antibodies before starting treatment and at regular intervals afterward. These tests measure not just whether you carry the virus, but how high your antibody levels are, expressed as an antibody index. An index above 0.9 strongly predicts that you’ll remain positive on future tests, signaling sustained risk. An index below 0.2 is more reassuring, though about 41% of people in that range eventually test positive later, so ongoing monitoring matters.
Your overall PML risk depends on a combination of factors: whether you carry the JC virus, how long you’ve been on the medication, and whether you’ve previously taken other immune-suppressing treatments. Doctors use this information to weigh the benefits of continuing therapy against the small but real risk of PML, and in some cases may recommend switching to a different medication if the risk profile becomes unfavorable.